Chinese patent expiration dates draw closer for Novo Nordisk

In coming years, Novo Nordisk will take blows in the shape of several patents terminating on the second-biggest market for the firm, a Danish media reports.

Photo: Thomas Borberg

After a string of years characterized by growth for Novo Nordisk, in 2022, the Danish pharmaceutical firm has been hit by a large pricing reform in China. More challenges loom on the horizon in the country, which is the firm’s second-biggest market, as reported by Danish media Finans.

This is because the company’s patent protection on some products are slated to terminate in coming years – starting with Tresiba, Ryzodeg, and Xultophy in 2024. Two years later, the patent for Novo Nordisk’s bestselling drug, GLP-1-based Ozempic, will expire in 2026.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs